MTN-016 Training Protocol v2.0 MTN-016 EMBRACE: Evaluation of Maternal and Baby Outcomes Registry After Chemoprophylactic Exposure.

Slides:



Advertisements
Similar presentations
1 MTN-003 Study Specific Training Randomization Overview.
Advertisements

Clinical Research at JHP LNM – 02 October OutlineJHU- Administration Building History Influential studies- ◦ PEPI ◦ 052 Future Prospects.
Contraception/Pregnancies MTN 020. Why do we care? Participants must come off product during pregnancy and breastfeeding – Studies of dapivirine in pregnant.
Effectiveness of the National PMTCT Program in Rwanda
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
PROMISE Introduction to PROMISE Protocol May 6, 2009.
What type of study is this?
Interim analysis of a double- blind, placebo-controlled study with TMC207 in patients with Multi-Drug Resistant (MDR) Tuberculosis Karel de Beule, CDTL.
MTN-028 Study Overview Phase 1 Pharmacokinetic Trial of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048.
HIV Drug Development in Neonates - What Now? Linda L. Lewis, M.D. Medical Officer Division of Antiviral Drug Products FDA.
Community Medicine. The association between low birth weight and maternal smoking during pregnancy can be studied by obtaining smoking histories from.
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPACT) Group PROMISE (BREAST FEEDING) 1077 AAHU STC 2013 Group 2 Cedric Sturdevant,
Template for study specific training for Intrapartum Research Studies [ Please see guide before using this]
PREVALENCE OF ANAEMIA IN WOMEN AT SCREENING AND FOLLOW-UP IN A MICROBICIDE PHASE III TRIAL Hasinah Asmal, Dinesh Singh, Gita Ramjee HIV Prevention Research.
XIX International AIDS Conference
Microbicides for HIV Prevention Pamina M. Gorbach, Epidemiology & Infectious Diseases UCLA.
PMTCT Prevention of Mother to Child Transmission Version Aug 2011.
Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother to Child Transmission of HIV-1 in Thailand NEJM July 15, 2004 Lallemant et.
Jared Baeten, MD PhD Thesla Palanee, PhD Site trainings 2012
MTN-001 Phase 2 Adherence and Pharmacokinetic Study of Oral and Vaginal Preparations of Tenofovir Craig Hendrix, Alexandra Minnis, Vijayanand Guddera,
What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID,
TREATMENT OF SERO-DISCORDANT COUPLES: IMPLICATIONS FOR YOUNG PEOPLE JJ KUMWENDA (FRCP-UK)
The Microbicide Trials Network Group 3 Lindsay O. Bryant Danielle M. Campbell Alan D. Johnson Leroy Smith Jr. Kendra M. Taylor May 31, 2016.
Dapivirine Ring Previous Safety Experience MTN 020 Training.
Clinical Trials and Research A Guide for Community Advisory Board Members Participant Manual.
Microbicides The Population Council Experience and Future Directions Don E. Waldron Medical Director Don E. Waldron Medical Director.
MTN-016 TRAINING Infant HIV Testing Urvi M Parikh, Ph.D. University of Pittsburgh Pittsburgh, PA USA.
Looking Ahead to MTN-017 Ross D. Cranston MD, FRCP Microbicide Trials Network IRMA.
Phase III Microbicide Trials Update Dr. Lut Van Damme IAS Conference Sydney, Australia July 2007.
MATERNAL ANTIRETROVIRAL THERAPY AND INFANT OUTCOMES THROUGHOUT THE FIRST YEAR OF LIFE: results from the DREAM study in Dschang, Cameroon Taafo F, Doro.
Effect of Household Air Pollution Exposure during Pregnancy on Birth Weight Dr. Sudipto Roy, Tshencho Dorji, Pema Tshewang, Tshewang Dorji, Pema Khandu.
BACKGROUND Despite the well established link between fetal macrosomia and maternal diabetes, it is estimated that 80% of macrosomic babies are born to.
Cascade of Prevention of Mother-to-Child Transmission of HIV (PMTCT) for Option B+ Transition: Findings from a Cohort of a Nationally Representative Sample.
What is known about the safety of PrEP in pregnancy? Lynda Stranix-Chibanda.
Understanding the Rationale of the 2015 WHO Guidelines on PrEP IAS Satellite Session Heather Watts M.D. Office of the Global AIDS Coordinator July 18,
IMPAACT 2010 Protocol Specifications for Recruitment, Screening, and Enrollment No updates.
IMPAACT 2001 STUDY Mhembere T.P. (B. Pharm (Hons), MPH)
IMPAACT 2010 Screening Visits
IMPAACT 2010 Screening Visits
Module 4 (e) Pregnancy and Breast Feeding
Microbicides Trial Network
Management of Pregnancies
VESTED Quiz Game
A protocol in development IMPAACT Prevention Scientific Committee
On behalf of The MTN-020/ASPIRE Study Team
Delivery Visits: Key Concepts and Procedures
Dapivirine Safety MTN 025 Training.
MTN-036 Study of Extended Duration Dapivirine Vaginal Ring for HIV Prevention How do I know if I’m Eligible to join? Women who join the study must.
MTN-025 Study Specific Training
VESTED Quiz Game
ADOLESCENT PrEP STUDIES Shorai Mukaka, MBchB (UZ) 05 MAY 2017
Obstetric and paediatric HIV surveillance data from the UK and Ireland
Switch RPV-TDF-FTC from NVP-Based Regimen NEAR-Rwanda Trial
UZ-UCSF Annual Research Day 8 April 2016
MULTIPURPOSE PREVENTION TECHNOLOGY (MPT) PRODUCT PIPELINE & THEIR POTENTIAL ACCEPTABILITY AMONG ADOLESCENT GIRLS & YOUNG WOMEN Barbara Friedland, Population.
Delivery Visits: Key Concepts and Procedures
IMPAACT 2010 Screening Visits
Obstetric and paediatric HIV surveillance data from the UK and Ireland
Obstetric and paediatric HIV surveillance data from the UK and Ireland
Obstetric and paediatric HIV surveillance data from the UK and Ireland
Overview.
January 2014 Update Obstetric and paediatric HIV surveillance data from the UK and Ireland.
PrEP Pre-Exposure Prophylaxis
International studY iN collaboration with WHO September 2017
HPTN 082 Uptake and adherence to daily oral PrEP as a primary prevention strategy for young African women: A Vanguard Study.
MTN-037 Protocol Overview
No Conflict of Interest to Declare Sufia Dadabhai, PhD MHS Johns Hopkins Bloomberg School of Public Health Blantyre, Malawi
MTN-026 & MTN-033 Rectal Dapivirine Gel
Facilitator: Pawin Puapornpong
Overview of PrEP studies: UZCHS-CTRC experience
Presentation transcript:

MTN-016 Training Protocol v2.0

MTN-016 EMBRACE: Evaluation of Maternal and Baby Outcomes Registry After Chemoprophylactic Exposure

MTN-016 A prospective observational cohort investigation of women with exposures to active and non-active study agents in trials investigating candidate HIV prevention agents intended for HIV prevention and the infants resulting from those pregnancies.

Study Population  Participants who become or became pregnant during HIV prevention trials, or who have or had planned exposures in pregnancy safety studies, provided pregnancy outcome was <1 year from the date of the EMBRACE Screening/Enrollment Visit  The infants resulting from those pregnancies, provided infants have not yet reached their 1 year birth date.

MTN-016: EMBRACE Primary Objectives 1. To compare adverse pregnancy and delivery outcomes between participant mothers assigned to an active agent with those of mothers assigned to placebo/control. 2. To compare the prevalence of major malformations identified in the first year of life between infants of mothers assigned to an active agent with those of infants of mothers assigned to placebo/control.

MTN-016: EMBRACE Secondary Objectives 1. To compare growth parameters in the first year of life between infants of mothers assigned to an active agent with those of mothers assigned to placebo/control. 2. To evaluate the prevalence and persistence of HIV drug resistance mutations in plasma among HIV-infected infants.

MTN-016: EMBRACE MTN-016 parent protocols:  MTN-002: Ph 1 Maternal Single-Dose PK and Placental transfer of Tenofovir 1% Vaginal gel among Healthy Term Gravidas  MTN-008: Expanded Safety Investigation of Tenofovir 1% Gel in Pregnancy and Lactation  MTN-003: VOICE: Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disoproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women  MTN-020: ASPIRE: Phase 3 Safety and Effectiveness Trial of a Vaginal Matrix Ring Containing Dapivirine for the Prevention of HIV-1 Infection in Women

MTN-016 Participant Contributors Kampala Durban MRC Johannesburg: PRHU Aurum Harare Durban eThekwini Pittsburgh Birmingham Cape Town Lilongwe Blantyre Johannesburg: WRHI

MTN-016: EMBRACE Maternal Inclusion Criteria  Able and willing to provide informed consent.  During participation in parent protocol, has/had known confirmed pregnancy.  Able and willing to provide adequate locator information (defined in site SOPs) Maternal Exclusion Criteria  Any condition that would complicate study outcome data  Pregnancy outcome occurred > 1 year ago

MTN-016: EMBRACE Infant Inclusion Criteria  Written informed consent from parent(s)/guardian  Born to mother enrolled in EMBRACE Infant Exclusion Criteria  Any condition that would complicate study outcome data  Has reached 1 year birth date

MTN 016: EMBRACE Maternal Visit Schedule  Screening/Enrollment  Quarterly  (Pregnancy Outcome) Infant Visit Schedule  Newborn/Initial Visit  Months 1, 6 and 12